K. Panageas, E. Elkin, L. Deangelis, L. Ben-porat, and L. Abrey, Trends in survival from primary central nervous system lymphoma, 1975-1999, Cancer, vol.103, issue.11, pp.2466-72, 2005.
DOI : 10.7326/0003-4819-129-12-199812150-00005
URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.21481/pdf

J. Olson, C. Janney, R. Rao, J. Cerhan, P. Kurtin et al., The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma, Cancer, vol.77, issue.7, pp.1504-1514, 2002.
DOI : 10.1002/cncr.10851

K. Makino, H. Nakamura, T. Kino, H. Takeshima, and J. Kuratsu, Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan, Surgical Neurology, vol.66, issue.5, pp.503-509, 2006.
DOI : 10.1016/j.surneu.2006.05.055

L. Abrey, J. Yahalom, and L. Deangelis, Treatment for Primary CNS Lymphoma: The Next Step, Journal of Clinical Oncology, vol.18, issue.17, pp.3144-50, 2000.
DOI : 10.1200/JCO.2000.18.17.3144

S. Del-rio, M. Rousseau, A. Soussain, C. , R. D. Hoang-xuan et al., Primary CNS lymphoma in immunocompetent patients. The oncologist, pp.526-565, 2009.

K. Jahnke, A. Korfel, P. Martus, M. Weller, U. Herrlinger et al., High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma, Annals of Oncology, vol.16, issue.3, pp.445-454, 2005.
DOI : 10.1093/annonc/mdi075

K. Panageas, E. Elkin, L. Ben-porat, L. Deangelis, and L. Abrey, Patterns of treatment in older adults with primary central nervous system lymphoma, Cancer, vol.24, issue.6, pp.1338-1382, 2007.
DOI : 10.1016/0360-3016(92)90538-S

G. Illerhaus, R. Marks, G. Ihorst, R. Guttenberger, C. Ostertag et al., First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data metaanalysis Annals of oncology : official journal of the European Society for Medical Oncology Highdose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.2624, issue.1024, pp.1305-133865, 2006.

G. Illerhaus, F. Muller, F. Feuerhake, A. Schafer, C. Ostertag et al., High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system R- MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma, Haematologica. Blood, vol.93125, issue.19, pp.147-81403, 2008.

C. Soussain, S. Choquet, E. Fourme, D. Delgadillo, K. Bouabdallah et al., Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases, Haematologica, vol.97, issue.11, pp.1751-1757, 2012.
DOI : 10.3324/haematol.2011.060434

G. Illerhaus, . Kb, G. Ihorst, G. Egerer, M. Lamprecht et al., High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial, The Lancet Haematology, vol.3, issue.8, 2016.
DOI : 10.1016/S2352-3026(16)30050-3

N. Doolittle, A. Korfel, M. Lubow, E. Schorb, U. Schlegel et al., Longterm cognitive function, neuroimaging, and quality of life in primary CNS lymphoma Longterm follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Annals of oncology : official journal of the European Society for Medical Oncology Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group, Neurology. ESMO. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.812121, issue.1814, pp.84-92842, 2003.

E. Pulczynski, O. Kuittinen, M. Erlanson, H. Hagberg, A. Fossa et al., Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group, Haematologica, vol.100, issue.4, pp.534-574, 2015.
DOI : 10.3324/haematol.2014.108472

G. Olivier, A. Clavert, L. Lacotte-thierry, M. Gardembas, M. Escoffre-barbe et al., A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial American journal of hematology Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Annals of oncology : official journal of the European Society for Medical Oncology Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation, ESMO. Haematologica, vol.892698, issue.235, pp.1024-9608, 2013.

A. Ferreri, K. Cwynarski, E. Pulczynski, M. Ponzoni, M. Deckert et al., Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial, The Lancet Haematology, vol.3, issue.5, pp.217-244, 2016.
DOI : 10.1016/S2352-3026(16)00036-3

C. Gisselbrecht, B. Glass, N. Mounier, S. Gill, D. Linch et al., Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era, Journal of Clinical Oncology, vol.28, issue.27, pp.4184-90, 2010.
DOI : 10.1200/JCO.2010.28.1618

H. Auner, R. Szydlo, J. Hoek, H. Goldschmidt, A. Stoppa et al., Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years, Bone Marrow Transplantation, vol.73, issue.2, pp.209-224, 2015.
DOI : 10.1038/leu.2013.313

X. Thomas, S. Suciu, B. Rio, G. Leone, G. Broccia et al., > or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study, Autologous stem cell transplantation in elderly patients, pp.1837-42389, 2007.

D. Andorsky, M. Cohen, A. Naeim, and L. Pinter-brown, Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over, Bone Marrow Transplantation, vol.80, issue.9, pp.1219-1244, 2011.
DOI : 10.1111/j.1532-5415.1986.tb05480.x

D. Chihara, K. Izutsu, E. Kondo, R. Sakai, S. Mizuta et al., High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, Autologous stem cell transplant, pp.433-438, 2012.

. Comorbidities, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, pp.840-846, 2008.

M. Charlson, T. Szatrowski, J. Peterson, J. Gold, A. Hurria et al., Validation of a combined comorbidity index Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study, Journal of clinical epidemiology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.4729, issue.3525, pp.1245-513457, 1994.

A. Palumbo, S. Bringhen, M. Mateos, A. Larocca, T. Facon et al., Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. The Lancet Oncology Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report, pp.437-481, 2012.

P. Colombat, A. Lemevel, P. Bertrand, V. Delwail, P. Rachieru et al., High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group, Bone Marrow Transplantation, vol.18, issue.6, pp.417-437, 2006.
DOI : 10.1200/JCO.2003.09.139

M. Montemurro, T. Kiefer, F. Schuler, A. , H. Wolf et al., Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study, Annals of Oncology, vol.18, issue.4, pp.665-71, 2007.
DOI : 10.1093/annonc/mdl458

K. Miyao, R. Sakemura, K. Imai, T. Sakai, N. Tsushita et al., Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience, G. First-line autologous transplantation in stem cell primary CNS lymphoma. European journal of haematology, pp.152-160, 2005.

N. Alimohamed, A. Daly, C. Owen, P. Duggan, and D. Stewart, Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience, Leukemia & Lymphoma, vol.19, issue.5, pp.862-869, 2012.
DOI : 10.1016/S0140-6736(09)61416-1

M. Choi, E. Kang, D. Kim, Y. Ko, H. Seok et al., Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation, International Journal of Hematology, vol.21, issue.3, pp.346-54, 2013.
DOI : 10.1200/JCO.2003.09.139

C. Soussain, F. Suzan, K. Hoang-xuan, N. Cassoux, V. Levy et al., Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma, Journal of Clinical Oncology, vol.19, issue.3, pp.742-751, 2001.
DOI : 10.1200/JCO.2001.19.3.742